AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16449995 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a (3 megaunits three times per week for 2 years or until recurrence)
Number of subjects: 674
Study 16449995 — intervention group
Group type: COMPARATOR
Intervention: Placebo (OBS group)
Number of subjects: 674
Study 16449995 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha-2a
Number of subjects: 674
Study 15265090 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release oral morphine (SROM)
Number of subjects: 18
Study 15265090 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 18
Study 11682352 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/benserazide
Number of subjects: 0
Study 11682352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9644643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilia (inherited or acquired risk factors)
Number of subjects: 97
Study 9644643 — intervention group
Group type: COMPARATOR
Intervention: No thrombophilia
Number of subjects: 97
Study 9644643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombophilia
Number of subjects: 97
Study 9644643 — intervention group
Group type: COMPARATOR
Intervention: Normal hemostasis parameters
Number of subjects: 97
Study 7512335 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photocoagulation for subfoveal CNV
Number of subjects: 289
Study 3415805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg bid for 6 weeks
Number of subjects: 13
Study 3415805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 3415805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 13
Study 29722602 — intervention group
Group type: COMPARATOR
Intervention: Active IFC + laser sham (G1)
Number of subjects: 168
Study 29722602 — intervention group
Group type: COMPARATOR
Intervention: IFC sham + active laser (G2)
Number of subjects: 168
Study 29722602 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IFC + laser (G3)
Number of subjects: 168
Study 29722602 — intervention group
Group type: COMPARATOR
Intervention: IFC + laser sham (G4)
Number of subjects: 168
Study 28259776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (25 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Number of subjects: 875
Study 28259776 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (600 mg), Emtricitabine (200 mg), Tenofovir disoproxil fumarate (300 mg)
Number of subjects: 875
Study 28259776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine, Emtricitabine, Tenofovir alafenamide
Number of subjects: 875
Study 28259776 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz, Emtricitabine, Tenofovir disoproxil fumarate
Number of subjects: 875
Study 25096954 — intervention group
Group type: EXPERIMENTAL
Intervention: Partogram
Number of subjects: 400
Study 25096954 — intervention group
Group type: COMPARATOR
Intervention: No Partogram
Number of subjects: 400
Study 23884300 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted imaging (WB-DWI)
Number of subjects: 19
Study 23884300 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body diffusion-weighted imaging + whole-body contrast-enhanced magnetic resonance imaging (WB-DWI + WB-ceMRI)
Number of subjects: 19
Study 22011796 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented low-dye (ALD) taping
Number of subjects: 17
Study 22011796 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel-pain orthosis (HPO)
Number of subjects: 17
Study 22011796 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 17
Study 18276188 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (5 hours per night for four consecutive days)
Number of subjects: 16
Study 18276188 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake (BAC around 0.4-0.6 per thousand)
Number of subjects: 16
Study 18276188 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (13% O2 concentration)
Number of subjects: 16
Study 18276188 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery (8 hours of sleep)
Number of subjects: 16
Study 17416006 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ml/d amino acids PN therapy
Number of subjects: 72
Study 17416006 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml/d amino acids PN therapy
Number of subjects: 72
Study 17416006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amino acids PN therapy)
Number of subjects: 72
Study 14687310 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement providing the reference nutrient intake for all vitamins and trace elements
Number of subjects: 164
Study 14687310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 11560718 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital rehabilitation
Number of subjects: 105
Study 11560718 — intervention group
Group type: COMPARATOR
Intervention: Social services day centres augmented by visiting therapists
Number of subjects: 105
Study 11560718 — intervention group
Group type: EXPERIMENTAL
Intervention: Day centre model
Number of subjects: 105
Study 11560718 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative working in day centres
Number of subjects: 105
Study 9164880 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with angina and normal coronary arteries
Number of subjects: 47
Study 9164880 — intervention group
Group type: COMPARATOR
Intervention: Healthy postmenopausal women (Control)
Number of subjects: 47
Study 7956393 — intervention group
Group type: EXPERIMENTAL
Intervention: OKY-046 (200 mg twice a day for 3 days, 200 mg on the fourth day)
Number of subjects: 9
Study 7956393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3372915 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 0
Study 3372915 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroids pretreatment
Number of subjects: 0
Study 3372915 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids pretreatment
Number of subjects: 0
Study 31262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized streptokinase (250,000 IU/4 h)
Number of subjects: 60
Study 31262641 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized heparin (10,000 IU/4 h)
Number of subjects: 60
Study 31262641 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 60
Study 30008280 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 0
Study 28338362 — intervention group
Group type: EXPERIMENTAL
Intervention: T (50 mg/kg BM)
Number of subjects: 7
Study 28338362 — intervention group
Group type: COMPARATOR
Intervention: C (5 mg/kg BM)
Number of subjects: 7
Study 28338362 — intervention group
Group type: COMPARATOR
Intervention: C + T (5 mg/kg BM + 50 mg/kg BM)
Number of subjects: 7
Study 28338362 — intervention group
Group type: COMPARATOR
Intervention: P (5 mg/kg BM)
Number of subjects: 7
Study 25515936 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based educational programme (seven modules with activities, workshops, and class sessions)
Number of subjects: 2245
Study 25515936 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 2245
Study 23108482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 89
Study 23108482 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 89
Study 21418096 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month Diabetes Medication Assistance Service
Number of subjects: 524
Study 21418096 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month Diabetes Medication Assistance Service
Number of subjects: 524
Study 21418096 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Medication Assistance Service (both 6 and 12 months)
Number of subjects: 524
Study 18204348 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 to 0.4 mg/kg
Number of subjects: 25
Study 18204348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 22213489 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation Therapy (SMT)
Number of subjects: 272
Study 22213489 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Exercise with Advice (HEA)
Number of subjects: 272
Study 22213489 — intervention group
Group type: COMPARATOR
Intervention: Medication
Number of subjects: 272
Study 15766585 — intervention group
Group type: COMPARATOR
Intervention: C‐SE non‐etch (mild self‐etch adhesive applied without selective etching)
Number of subjects: 29
Study 15766585 — intervention group
Group type: EXPERIMENTAL
Intervention: C‐SE etch (mild self‐etch adhesive applied with selective etching)
Number of subjects: 29
Study 12364432 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 13
Study 12364432 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TAA)
Number of subjects: 13
Study 12364432 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BUD)
Number of subjects: 13
Study 12364432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10218691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5%
Number of subjects: 48
Study 10218691 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine 1.0%
Number of subjects: 48
Study 10218691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% buffered to pH 7.0
Number of subjects: 48
Study 10218691 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% diluted 1:1 with glutathione bicarbonate Ringer solution
Number of subjects: 48
Study 7828384 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200 mg/day)
Number of subjects: 53
Study 7828384 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (80 mg/day)
Number of subjects: 53
Study 2225899 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylic palatal stabilizing device (PSD)
Number of subjects: 26
Study 2225899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PSD)
Number of subjects: 26
Study 755862 — intervention group
Group type: EXPERIMENTAL
Intervention: Fading plus feedback training
Number of subjects: 0
Study 755862 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 0
Study 12045410 — intervention group
Group type: EXPERIMENTAL
Intervention: Early life events (including prenatal factors, infections, diet, and allergen exposure)
Number of subjects: 0
Study 31320354 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiogram with pacemaker check
Number of subjects: 1200
Study 31320354 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up with pacemaker check alone
Number of subjects: 1200
Study 31320354 — intervention group
Group type: EXPERIMENTAL
Intervention: External validation of risk stratification model
Number of subjects: 1200
Study 31320354 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 1200
Study 29868877 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased direct supervision (attending physicians joined work rounds)
Number of subjects: 1259
Study 29868877 — intervention group
Group type: COMPARATOR
Intervention: Standard supervision (attending physicians available but did not join work rounds)
Number of subjects: 1259
Study 29868877 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased direct supervision
Number of subjects: 1259
Study 29868877 — intervention group
Group type: COMPARATOR
Intervention: Standard supervision
Number of subjects: 1259
Study 26676309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (Minirin Melt) 60 μg
Number of subjects: 249
Study 26676309 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual desmopressin (Minirin Melt) 120 μg
Number of subjects: 249
Study 26676309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 30 mg im ketorolac and 60 μg sublingual desmopressin
Number of subjects: 249
Study 26676309 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine (30 mg im)
Number of subjects: 249
Study 26676309 — intervention group
Group type: COMPARATOR
Intervention: NSAID group (ketorolac)
Number of subjects: 249
Study 24872119 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer adherence support intervention
Number of subjects: 340
Study 24872119 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 340
Study 22334420 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Radial Approach (LRA)
Number of subjects: 1000
Study 22334420 — intervention group
Group type: COMPARATOR
Intervention: Right Radial Approach (RRA)
Number of subjects: 1000
Study 22334420 — intervention group
Group type: COMPARATOR
Intervention: Crossover to femoral
Number of subjects: 1000
Study 22334420 — intervention group
Group type: COMPARATOR
Intervention: Operator-reported subclavian tortuosity
Number of subjects: 1000
Study 20933145 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) for 15 minutes, 5 times a week for 1 month
Number of subjects: 16
Study 20933145 — intervention group
Group type: COMPARATOR
Intervention: Social visits for 15 minutes, 5 times a week for 1 month
Number of subjects: 16
Study 17682938 — intervention group
Group type: EXPERIMENTAL
Intervention: Non‐occupational post‐exposure prophylaxis (NPEP)
Number of subjects: 0
Study 15673854 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 96
Study 15673854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 96
Study 15673854 — intervention group
Group type: COMPARATOR
Intervention: Thiopental
Number of subjects: 96
Study 12923444 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise on a lumbar extensor machine for 6 months
Number of subjects: 16
Study 12923444 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16
Study 10479611 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief phone counseling (up to two short calls)
Number of subjects: 714
Study 10479611 — intervention group
Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 714
Study 10479611 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief phone counseling
Number of subjects: 714
Study 9023388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bepanthen cream applied to randomly selected parts of treatment fields
Number of subjects: 86
Study 9023388 — intervention group
Group type: COMPARATOR
Intervention: No topical ointment (control)
Number of subjects: 86
Study 2003042 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (300 micrograms/day)
Number of subjects: 20
Study 2003042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6370439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprozin 1,200 mg once daily
Number of subjects: 125
Study 6370439 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone 100 mg four times daily
Number of subjects: 125
Study 6370439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 30801370 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar Locking Plate (VLP)
Number of subjects: 166
Study 30801370 — intervention group
Group type: COMPARATOR
Intervention: Augmented External Fixation (EF)
Number of subjects: 166
Study 29786537 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 190
Study 29786537 — intervention group
Group type: COMPARATOR
Intervention: XIENCE EES
Number of subjects: 190
Study 27484605 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (Damon Q™)
Number of subjects: 15
Study 27484605 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligating brackets (Mini Master Series)
Number of subjects: 15
Study 24587262 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (VCZ)
Number of subjects: 147
Study 24587262 — intervention group
Group type: COMPARATOR
Intervention: Conventional amphotericin B (CAB)
Number of subjects: 147
Study 21741739 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical excision
Number of subjects: 50
Study 21741739 — intervention group
Group type: COMPARATOR
Intervention: Surgical curettage
Number of subjects: 50
Study 20101773 — intervention group
Group type: COMPARATOR
Intervention: Endoscopy-based long-term study
Number of subjects: 10
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 fatty acids
Number of subjects: 476
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 476
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid
Number of subjects: 476
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid
Number of subjects: 476
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Arachidonic acid
Number of subjects: 476
Study 17585059 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid
Number of subjects: 476
Study 15826468 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 24
Study 15826468 — intervention group
Group type: COMPARATOR
Intervention: Control group (younger patients under 55 years)
Number of subjects: 24
Study 12056707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine (1250 mg/m2 twice daily, on days 1‐14 every 21 days)
Number of subjects: 1207
Study 12056707 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5‐FU/leucovorin (Mayo Clinic regimen)
Number of subjects: 1207
Study 12056707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 1207
Study 12056707 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5‐FU/leucovorin
Number of subjects: 1207
Study 10496113 — intervention group
Group type: EXPERIMENTAL
Intervention: CES plus low dose caffeine (150 mg/l)
Number of subjects: 15
Study 10496113 — intervention group
Group type: EXPERIMENTAL
Intervention: CES plus medium dose caffeine (225 mg/l)
Number of subjects: 15
Study 10496113 — intervention group
Group type: COMPARATOR
Intervention: CES placebo (68.8 g/l)
Number of subjects: 15
Study 10496113 — intervention group
Group type: COMPARATOR
Intervention: Water placebo
Number of subjects: 15
Study 7778921 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 1:100,000 epinephrine (n = 39)
Number of subjects: 72
Study 7778921 — intervention group
Group type: COMPARATOR
Intervention: 1% lidocaine (n = 33)
Number of subjects: 72
Study 1964620 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg four times daily)
Number of subjects: 31
Study 1964620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 6162280 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation therapy combined with vitamin A palmitate (1.5 million IU/day; total dose 30 million IU), applied orally
Number of subjects: 42
Study 6162280 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 42
Study 6162280 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation therapy combined with vitamin A palmitate
Number of subjects: 42
Study 6162280 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 42
Study 30692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in fasted condition
Number of subjects: 287
Study 30692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in high-fat/low-caloric condition
Number of subjects: 287
Study 30692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-Piperaquine Phosphate (DHA-PQP) in high-fat/high-caloric breakfast
Number of subjects: 287
Study 30692558 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine (A-L) in fed state
Number of subjects: 287
Study 30692558 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (placebo-controlled)
Number of subjects: 287
Study 28122892 — intervention group
Group type: EXPERIMENTAL
Intervention: alemtuzumab 30 mg by intravenous infusion every other day three times a week for 12 weeks
Number of subjects: 6
Study 26100413 — intervention group
Group type: EXPERIMENTAL
Intervention: Once monthly administration of vitamin D3 (25,000 IU)
Number of subjects: 100
Study 26100413 — intervention group
Group type: COMPARATOR
Intervention: Daily administration of a fixed-dose combination of vitamin D3 (800 IU) and calcium (1000 mg)
Number of subjects: 100
Study 24045936 — intervention group
Group type: EXPERIMENTAL
Intervention: Native tissue vs. graft-augmented rectocele repair (specific intervention details not provided)
Number of subjects: 125
Study 24045936 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative defecatory or incontinence symptoms
Number of subjects: 125
Study 23008077 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized prescribing portrait on statins with therapeutic recommendations (intervention group)
Number of subjects: 2725
Study 23008077 — intervention group
Group type: COMPARATOR
Intervention: Delayed control group (control group)
Number of subjects: 2725
Study 23008077 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized prescribing portrait on statins (intervention group)
Number of subjects: 2725
Study 19386747 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower protein formula (1.77 and 2.2 g protein/100 kcal)
Number of subjects: 1138
Study 19386747 — intervention group
Group type: COMPARATOR
Intervention: Higher protein formula (2.9 and 4.4 g protein/100 kcal)
Number of subjects: 1138
Study 19386747 — intervention group
Group type: COMPARATOR
Intervention: Breastfed group
Number of subjects: 1138
Study 17244173 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 21
Study 17244173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 15660234 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Number of subjects: 120